{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T10:54:48Z","timestamp":1770461688804,"version":"3.49.0"},"reference-count":33,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"44","license":[{"start":{"date-parts":[[2021,11,5]],"date-time":"2021-11-05T00:00:00Z","timestamp":1636070400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:sec>\n            <jats:title>Abstract<\/jats:title>\n            <jats:p>Patients with metabolic syndrome are at a higher risk of nonalcoholic fatty liver disease (NAFLD) and liver fibrosis than the general population. Still, accessibility of screening method for NAFLD with significant fibrosis, such as transient elastography (FibroScan) are limited in some settings. This study aimed to develop a simple clinical predictive score for detecting NAFLD with significant fibrosis in patients with metabolic syndrome.<\/jats:p>\n            <jats:p>A cross-sectional study was designed to obtain the data from medical records of all relevant patients who underwent transient elastography between January 2011 and December 2020 at Siriraj Hospital, Thailand. A liver stiffness cutoff value of 7.0\u200akilopascal was used to define the presence of significant liver fibrosis. To examine potential predictors, medical history and clinical data commonly assessed in routine practice were selected by following expert opinions and univariable statistical analysis. Backward and forward stepwise logistic regression was performed to acquire a final prediction model. To simplify the model, a weighted score was assigned for each categorized predictor. In addition, eligible cutoff values of the score and their predictive performances were determined.<\/jats:p>\n            <jats:p>A total of 745 medical records were reviewed. The prevalence of NAFLD with significant fibrosis in patients with metabolic syndrome was 12.6%. Most clinical characteristics of patients with NAFLD with significant fibrosis and those non-NAFLD and NAFLD with no\/mild fibrosis were quite disparate. The most practical model comprised globulin, aspartate transaminase, platelet count, and type 2 diabetes. It provided a good predictive performance with an area under the receiver operating characteristic curve of 0.828 (95% confidence interval [CI]: 0.782, 0.874). At the proper cutoff value, sensitivity and specificity were 76.6% (95% CI: 66.7%, 84.7%) and 72.4% (95% CI: 68.7%, 75.8%), respectively. The likelihood ratio of testing positive for NAFLD with significant fibrosis was 2.8 (95% CI: 2.34, 3.27) among patients with scores above the cutoff value.<\/jats:p>\n            <jats:p>The first score for detecting of NAFLD with significant fibrosis in patients with metabolic syndrome was developed. This practical score, providing a good predictive performance, should be useful to help clinicians prioritize needs for further investigations among high-risk patients, especially in resource-limited settings.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000027640","type":"journal-article","created":{"date-parts":[[2021,12,9]],"date-time":"2021-12-09T20:45:55Z","timestamp":1639082755000},"page":"e27640","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Clinical predictive score for detecting nonalcoholic fatty liver disease with significant fibrosis in patients with metabolic syndrome"],"prefix":"10.1097","volume":"100","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7182-0733","authenticated-orcid":false,"given":"Chayanis","family":"Kositamongkol","sequence":"first","affiliation":[{"name":"Department of Clinical Epidemiology, Faculty of Medicine, Thammasat University, Pathumthani, Thailand"},{"name":"Division of Ambulatory Medicine, Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3783-6691","authenticated-orcid":false,"given":"Thammanard","family":"Charernboon","sequence":"additional","affiliation":[{"name":"Department of Clinical Epidemiology, Faculty of Medicine, Thammasat University, Pathumthani, Thailand"},{"name":"Center of Excellence in Applied Epidemiology, Thammasat University, Pathumthani, Thailand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8792-4729","authenticated-orcid":false,"given":"Thanet","family":"Chaisathaphol","sequence":"additional","affiliation":[{"name":"Division of Ambulatory Medicine, Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3078-0541","authenticated-orcid":false,"given":"Chaiwat","family":"Washirasaksiri","sequence":"additional","affiliation":[{"name":"Division of Ambulatory Medicine, Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5314-9966","authenticated-orcid":false,"given":"Chonticha","family":"Auesomwang","sequence":"additional","affiliation":[{"name":"Division of Ambulatory Medicine, Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5083-165X","authenticated-orcid":false,"given":"Tullaya","family":"Sitasuwan","sequence":"additional","affiliation":[{"name":"Division of Ambulatory Medicine, Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8334-0267","authenticated-orcid":false,"given":"Phunchai","family":"Charatcharoenwitthaya","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1995-4405","authenticated-orcid":false,"given":"Pochamana","family":"Phisalprapa","sequence":"additional","affiliation":[{"name":"Division of Ambulatory Medicine, Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2021,11,5]]},"reference":[{"key":"R1-20250504","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/hep.28431","article-title":"Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes","volume":"64","author":"Younossi","year":"2016","journal-title":"Hepatology"},{"key":"R2-20250504","first-page":"01","article-title":"NASH\/liver fibrosis prevalence and incidence of non-liver comorbidities among people with NAFLD and incidence of NAFLD by metabolic comorbidites: lessons from South Korea","author":"Park","year":"2021","journal-title":"Dig Dis"},{"key":"R3-20250504","doi-asserted-by":"crossref","first-page":"3361","DOI":"10.3748\/wjg.v24.i30.3361","article-title":"Current guidelines for the management of non-alcoholic fatty liver disease: a systematic review with comparative analysis","volume":"24","author":"Leoni","year":"2018","journal-title":"World J Gastroenterol"},{"key":"R4-20250504","doi-asserted-by":"crossref","first-page":"i4428","DOI":"10.1136\/bmj.i4428","article-title":"Non-alcoholic fatty liver disease (NAFLD): summary of NICE guidance","volume":"354","author":"Glen","year":"2016","journal-title":"BMJ"},{"key":"R5-20250504","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.jhep.2015.11.004","article-title":"EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease","volume":"64","year":"2016","journal-title":"J Hepatol"},{"key":"R6-20250504","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/hep.29367","article-title":"The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases","volume":"67","author":"Chalasani","year":"2018","journal-title":"Hepatology"},{"key":"R7-20250504","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1053\/j.gastro.2019.11.312","article-title":"MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease","volume":"158","author":"Eslam","year":"2020","journal-title":"Gastroenterology"},{"key":"R8-20250504","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1053\/j.gastro.2015.04.043","article-title":"Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease","volume":"149","author":"Angulo","year":"2015","journal-title":"Gastroenterology"},{"key":"R9-20250504","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/S2468-1253(16)30205-9","article-title":"Prevalence of clinically significant liver disease within the general population, as defined by non-invasive markers of liver fibrosis: a systematic review","volume":"2","author":"Harris","year":"2017","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"R10-20250504","doi-asserted-by":"crossref","first-page":"01","DOI":"10.3390\/nu12010015","article-title":"Ethnicity and metabolic syndrome: implications for assessment, management and prevention","volume":"12","author":"Lear","year":"2019","journal-title":"Nutrients"},{"key":"R11-20250504","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1016\/j.jhep.2012.11.021","article-title":"Non-invasive diagnosis of non-alcoholic fatty liver disease. A critical appraisal","volume":"58","author":"Machado","year":"2013","journal-title":"J Hepatol"},{"key":"R12-20250504","doi-asserted-by":"crossref","first-page":"638","DOI":"10.4254\/wjh.v7.i4.638","article-title":"Non-invasive methods for the diagnosis of nonalcoholic fatty liver disease","volume":"7","author":"Papagianni","year":"2015","journal-title":"World J Hepatol"},{"key":"R13-20250504","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1002\/hep.29302","article-title":"Comparison of laboratory tests, ultrasound, or magnetic resonance elastography to detect fibrosis in patients with nonalcoholic fatty liver disease: a meta-analysis","volume":"66","author":"Xiao","year":"2017","journal-title":"Hepatology"},{"key":"R14-20250504","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/S2468-1253(20)30077-7","article-title":"Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease: a systematic review and meta-analysis","volume":"5","author":"Ye","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"R15-20250504","doi-asserted-by":"crossref","first-page":"W1","DOI":"10.7326\/M14-0698","article-title":"Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): explanation and elaboration","volume":"162","author":"Moons","year":"2015","journal-title":"Ann Intern Med"},{"key":"R16-20250504","doi-asserted-by":"crossref","first-page":"e012799","DOI":"10.1136\/bmjopen-2016-012799","article-title":"STARD 2015 guidelines for reporting diagnostic accuracy studies: explanation and elaboration","volume":"6","author":"Cohen","year":"2016","journal-title":"BMJ Open"},{"key":"R17-20250504","doi-asserted-by":"crossref","first-page":"W1","DOI":"10.7326\/0003-4819-138-1-200301070-00012-w1","article-title":"The STARD statement for reporting studies of diagnostic accuracy: explanation and elaboration","volume":"138","author":"Bossuyt","year":"2003","journal-title":"Ann Intern Med"},{"key":"R19-20250504","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1242\/dmm.001180","article-title":"A comprehensive definition for metabolic syndrome","volume":"2","author":"Huang","year":"2009","journal-title":"Dis Model Mech"},{"key":"R20-20250504","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.2337\/diacare.27.5.1182","article-title":"Can we apply the national cholesterol education program adult treatment panel definition of the metabolic syndrome to Asians?","volume":"27","author":"Tan","year":"2004","journal-title":"Diabetes Care"},{"key":"R21-20250504","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.1161\/CIRCULATIONAHA.105.169404","article-title":"Diagnosis and management of the metabolic syndrome: an American Heart Association\/National Heart, Lung, and Blood Institute Scientific Statement","volume":"112","author":"Grundy","year":"2005","journal-title":"Circulation"},{"key":"R22-20250504","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.cld.2017.08.004","article-title":"Diagnosis and evaluation of nonalcoholic fatty liver disease\/nonalcoholic steatohepatitis, including noninvasive biomarkers and transient elastography","volume":"22","author":"Tsai","year":"2018","journal-title":"Clin Liver Dis"},{"key":"R23-20250504","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1136\/gut.2005.069153","article-title":"Diagnosis of cirrhosis by transient elastography (FibroScan): a prospective study","volume":"55","author":"Foucher","year":"2006","journal-title":"Gut"},{"key":"R24-20250504","first-page":"411","article-title":"What you see may not be what you get: a brief, nontechnical introduction to overfitting in regression-type models","volume":"66","author":"Babyak","year":"2004","journal-title":"Psychosom Med"},{"key":"R25-20250504","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1111\/liv.13413","article-title":"Clinical risk scoring for predicting non-alcoholic fatty liver disease in metabolic syndrome patients (NAFLD-MS score)","volume":"37","author":"Saokaew","year":"2017","journal-title":"Liver Int"},{"key":"R26-20250504","doi-asserted-by":"crossref","first-page":"339","DOI":"10.3348\/kjr.2016.17.3.339","article-title":"How to develop, validate, and compare clinical prediction models involving radiological parameters: study design and statistical methods","volume":"17","author":"Han","year":"2016","journal-title":"Korean J Radiol"},{"key":"R28-20250504","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/j.jclinepi.2006.01.014","article-title":"Review: a gentle introduction to imputation of missing values","volume":"59","author":"Donders","year":"2006","journal-title":"J Clin Epidemiol"},{"key":"R29-20250504","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/s12889-017-4041-1","article-title":"Prevalence and trends of metabolic syndrome among adults in the asia-pacific region: a systematic review","volume":"17","author":"Ranasinghe","year":"2017","journal-title":"BMC Public Health"},{"key":"R30-20250504","first-page":"321","article-title":"What is the normal serum alanine aminotransferase (ALT) value for Thai subjects with the low risk of liver diseases?","volume":"57","author":"Viriyautsahakul","year":"2013","journal-title":"Chula Med J"},{"key":"R31-20250504","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1111\/j.1440-1746.2012.07143.x","article-title":"Upper limit of normal serum alanine and aspartate aminotransferase levels in Korea","volume":"28","author":"Sohn","year":"2013","journal-title":"J Gastroenterol Hepatol"},{"key":"R32-20250504","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1186\/1471-2458-10-454","article-title":"Alcohol, metabolic risk and elevated serum gamma-glutamyl transferase (GGT) in Indigenous Australians","volume":"10","author":"Haren","year":"2010","journal-title":"BMC Public Health"},{"key":"R33-20250504","doi-asserted-by":"crossref","first-page":"15080","DOI":"10.1038\/nrdp.2015.80","article-title":"Nonalcoholic fatty liver disease","volume":"1","author":"Brunt","year":"2015","journal-title":"Nat Rev Dis Primers"},{"key":"R34-20250504","doi-asserted-by":"crossref","first-page":"407","DOI":"10.14366\/usg.20147","article-title":"Liver stiffness quantification in biopsyproven nonalcoholic fatty liver disease patients using shear wave elastography in comparison with transient elastography","volume":"40","author":"Taibbi","year":"2020","journal-title":"Ultrasonography"},{"key":"R35-20250504","doi-asserted-by":"crossref","first-page":"01","DOI":"10.3390\/ijms21165888","article-title":"History of nonalcoholic fatty liver disease","volume":"21","author":"Lonardo","year":"2020","journal-title":"Int J Mol Sci"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000027640","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T07:03:38Z","timestamp":1746342218000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000027640"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,5]]},"references-count":33,"journal-issue":{"issue":"44","published-online":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000027640","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,5]]},"assertion":[{"value":"2021-03-31","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-10-13","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}